Inhibrx Biosciences, Inc.

Directions Website

Inhibrx Biosciences, Inc. At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions.

November is Lung Cancer Awareness Month, a time to recognize people living with lung cancer, along with the families, ca...
11/04/2026

November is Lung Cancer Awareness Month, a time to recognize people living with lung cancer, along with the families, caregivers, and healthcare professionals who support them.

Despite advances in research and treatment, significant unmet needs remain for people affected by lung cancer. At Inhibrx, we remain committed to advancing oncology research, including the ongoing investigation of INBRX-106 in non-small cell lung cancer (NSCLC), as part of our broader efforts to explore potential new therapeutic approaches for patients.

Learn more about the INBRX-106 program: https://tinyurl.com/55whrp5m

Our team is in Miami for the 2026 MSTS Annual Meeting and is looking forward to engaging with the musculoskeletal oncolo...
10/29/2026

Our team is in Miami for the 2026 MSTS Annual Meeting and is looking forward to engaging with the musculoskeletal oncology community.

If you’re attending, stop by Booth #1 to connect with our team and learn more about our ozekibart (INBRX-109) program here: https://tinyurl.com/y38wkwy6

Our team is onsite at the 2026 ESMO Congress and looking forward to engaging with the oncology community.Stop by our exh...
10/25/2026

Our team is onsite at the 2026 ESMO Congress and looking forward to engaging with the oncology community.

Stop by our exhibit booth ( #1077 in Hall 10) to learn more about our ongoing research.

10/22/2026

Inhibrx is heading to the 2026 ESMO Congress in Madrid, where data from the primary analysis of the phase 2 HexAgon-HN study evaluating ordastobart (INBRX-106) in first-line recurrent/metastatic head and neck squamous cell carcinoma will be presented.

Oral Presentation | Abstract LBA42
Sunday, October 25
8:30–8:40 AM CET
Lead Author: Jong Chul Park

Visit our exhibit booth ( #1077, Hall 10) to connect with our team and learn more about our ongoing research.

View the session details: https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/251

Inhibrx will present data from our randomized, registrational Phase 2 ChonDRAgon study evaluating ozekibart (INBRX-109) ...
10/21/2026

Inhibrx will present data from our randomized, registrational Phase 2 ChonDRAgon study evaluating ozekibart (INBRX-109) in conventional chondrosarcoma at the 2026 MSTS Annual Meeting in Miami.

Oral Presentation | Abstract 19
Thursday, October 29
Session: 2:50–3:40 PM EST
Lead Author: Robin Jones

Inhibrx will also participate in the Industry Innovation Symposium earlier that day.

Attending MSTS? Visit us at Booth #1 to connect with our team and learn more about our ongoing research.

Our team took a well-deserved timeout during the day to celebrate Oktoberfest the right way—grilling up brats, sharing p...
10/16/2026

Our team took a well-deserved timeout during the day to celebrate Oktoberfest the right way—grilling up brats, sharing plenty of laughs, and enjoying great company.

Stepping away from the lab and our screens to connect, unwind, and recharge together keeps our team culture strong.

Grateful for this amazing crew.

Thank you, Culture Club, for organizing another fun event.

Our team came together onsite for Inhibrx Day, a chance to connect, share insights, and recognize the people behind our ...
10/05/2026

Our team came together onsite for Inhibrx Day, a chance to connect, share insights, and recognize the people behind our work.

We’re grateful for the collaboration, dedication, and passion each team member brings to Inhibrx.

Every day, our hard work and contributions help advance our mission of bringing hope and innovative treatment options to patients in need.

Our commitment to advancing research in rare cancers extends to Ewing sarcoma.At Inhibrx, we are actively investigating ...
09/26/2026

Our commitment to advancing research in rare cancers extends to Ewing sarcoma.

At Inhibrx, we are actively investigating ozekibart (INBRX-109) in patients with Ewing sarcoma, with the goal of exploring potential new treatment options for this rare cancer.

Learn more about the study details and eligibility: https://tinyurl.com/6w46a4hm

World Cancer Research Day highlights the continued importance of research in advancing our understanding of cancer and s...
09/24/2026

World Cancer Research Day highlights the continued importance of research in advancing our understanding of cancer and supporting scientific progress across oncology.

At Inhibrx, our research efforts draw on our understanding of target biology and protein-engineering to support the discovery and development of biologic therapeutics.

Learn more about our scientific approach: https://tinyurl.com/hbruccuh

Inhibrx is proud to support the Northwest Sarcoma Foundation and join the 2026 Dragonslayer Fantasy Dash & Strut in Port...
09/12/2026

Inhibrx is proud to support the Northwest Sarcoma Foundation and join the 2026 Dragonslayer Fantasy Dash & Strut in Portland.

Today’s event brings together the sarcoma community for a day of connection and movement.

We’re grateful to take part alongside everyone supporting the sarcoma community.

Address

Torrey Pines Science Park 11025 N Torrey Pines Road #200
La Jolla, CA
92037

Alerts

Be the first to know and let us send you an email when Inhibrx Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Nearby engineering companies